DDInter16 DDInter1082
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Acetohexamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tromethamine
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Trovafloxacin
Acetohexamide {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib
Acetohexamide may lead to a major life threatening interaction when taken with Trovafloxacin
Acetohexamide may lead to a major life threatening interaction when taken with Fluconazole